Table 2. Treatment characteristics for patients treated with neoadjuvant chemotherapy.

Variables	Entire cohort (n=36)	Gemcitabine (n=17)	Multi-agent (n=19)	P value
First line chemotherapy, n (%)
Gemcitabine	17 (47.2)	17 (100.0)	0 (0.0)
Gem/nab-paclitaxel	8 (22.2)	0 (0.0)	8 (42.1)
FOLFIRINOX	11 (30.6)	0 (0.0)	11 (57.9)
Median CA19-9 change (IQR)	−8 (−55 to 0)	−9 (−46.5 to 0.5)	−2 (−63.5 to 0)	0.95
Surgical decision, n (%)				0.48
Proceed to surgery	29 (80.6)	13 (76.5)	16 (84.2)
Distant progression	3 (8.3)	2 (11.8)	1 (5.3)
Local progression	0 (0.0)	0 (0.0)	0 (0.0)
Clinical decision	4 (11.1)	2 (11.8)	2 (10.5)